- cafead Jan 25, 2021 at 11:32: AM
via Bristol Myers Squibb snagged an FDA go-ahead to open another front in Opdivo's rivalry with Merck & Co.'s Keytruda.
The FDA approved the combination of Opdivo and Exelixis’ tyrosine kinase inhibitor Cabometyx for previously untreated advanced renal cell carcinoma—the exact same indication Merck and Pfizer’s PD-1/TKI pairing, Keytruda and Inlyta, won back in April 2019.
article source
The FDA approved the combination of Opdivo and Exelixis’ tyrosine kinase inhibitor Cabometyx for previously untreated advanced renal cell carcinoma—the exact same indication Merck and Pfizer’s PD-1/TKI pairing, Keytruda and Inlyta, won back in April 2019.
article source